Initiate patient recruitment for the global Phase 3 study

Not delivered by the deadline

AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.

Announced: 14 Aug 2025
Due: 31 Dec 2025
Checked: 1 Oct 2026

Deadline
Met
Late
Not met
Today

What the company said

“global Phase 3 study activities ongoing including qualification of identified sites with patient recruitment expected to initiate later this year”

SourceLarimar Therapeutics, Inc. Form 8-K press release, 2025-08-14
FilingSEC filing index
Deadline as statedlater this year
Deadline used31 Dec 2025, the last day of the stated period
TypeProduct
Permanent referenceKI-C-2025-LRMR-003062
Cite as https://keptindex.org/c/KI-C-2025-LRMR-003062/ — this address never changes.

What we found

Evidence strength A What the grades mean

The company did not initiate patient recruitment in 2025; subsequent filings indicate plans to initiate screening in the second quarter of 2026.

A
Larimar Therapeutics, Inc. 10-K filed 2026-03-19 Regulatory filing · published 19 Mar 2026 · retrieved 1 Oct 2026 · kept permanently by the SEC · fingerprint b14f668ecba6
“we plan to initiate screening in this Phase 3 study in the second quarter of 2026” ✓ confirmed on the page

Market reaction: the shares moved +9.5% against the S&P 500 over the three sessions around the disclosure (18 Mar 2026 to 23 Mar 2026). What this measures

Checked 1 Oct 2026.

Commitment lineage

Every time the company restated this commitment. The original is never changed, and the outcome is always measured against version 1.

1 versions

Version 1 · original · stated 14 Aug 2025

Deadline 31 Dec 2025 (“later this year”) · wording expected
Version 2 · stated 24 Feb 2026

Deadline 30 Jun 2026 (“Q2 2026”)

“Initiate screening Q2 2026”
Source for this version

Commitment DNA

The structured record of this commitment. Fields the company did not state are left blank rather than guessed.

Event type: Clinical milestone
Indicative materiality: Medium rules
Action: Initiate
Deliverable: Phase 3 patient recruitment
Language: Expected (“expects”, “plans”)
In the company’s control: High
Specificity: Medium

How this entry was checked

Commitment recordedThe company's words were matched word for word against the filing.
First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Third check on a negative finding: agreesBecause a negative finding could harm a company if wrong, a stronger model re-read the evidence fully blind and reached the same answer.

Confirmed. This outcome counts towards the company's Kept Score. How verification works

Are you Larimar Therapeutics, Inc.? You can publish an official statement next to this entry, free. Add a statement.

Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.